What was studied?
Nineteen adults with biopsy-confirmed chronic active hepatitis C entered a randomized, double-blind pilot trial. Researchers followed a six-month treatment phase with six additional months of observation, measuring liver enzymes and HCV RNA.
What did the researchers report?
No participant cleared HCV RNA. Overall liver-enzyme changes were not significant between the reported periods; one transient normalization in an active-group participant was followed by relapse. The authors did not find the regimen effective.
What are the limits?
This is historical evidence from a small study, not current hepatitis C treatment guidance. A plausible immune mechanism did not translate into the investigated outcomes. The result cannot support broad immune-enhancement claims or efficacy promises for laboratory materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.